Get started
ImmunityBio, Inc.ImmunityBio, Inc.ImmunityBio, Inc.

ImmunityBio, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

IBRX trade ideas

IBRX - Biotech Short Squeeze Candidate - High Risk / High RewardImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe. Investment Summary Shares in Circulation: 53.472M Short Float: 34.19% Recent Development: Launch of bladder cancer treatment Anktiva in the US has positively impacted shares. Critical Range for Continuation: $7.90 - $8.50 Technical Analysis Current Resistance Levels: $10.50 and $12.50 Target Price (Take Profit): $14.00 Stop Loss: Set at under $5.30 Trading Strategy Entry Point: Monitor the critical range of $7.90 to $8.50. If the stock breaks above this range with strong volume, it might signal a continuation of the upward trend. Profit Target: Set your take profit at $14.00, considering the recent positive news and technical setup. Risk Management: Place a stop loss slightly below $5.30 to protect against significant losses if the stock reverses. Considerations Market Conditions: Keep an eye on the overall market conditions, as they can influence the stock's performance. News Updates: Stay updated on any news related to ImmunityBio, especially regarding FDA approvals, clinical trials, and product launches. Short Squeeze Potential: Given the high short float of 34.19%, there is potential for a short squeeze, which could drive the stock price higher rapidly. Chart Analysis Review the attached chart for detailed price trends and movements. Pay attention to key technical indicators such as moving averages, RSI, and MACD for further insights into the stock’s momentum and potential reversals. Trading Advisory Exercise caution and align your trading actions with your risk tolerance and market conditions. Conduct comprehensive research or consult with a financial advisor to tailor the strategy to your individual circumstances. Disclaimer This content is for informational purposes only and should not be considered financial advice. By following this strategic approach, you can potentially capitalize on the recent positive developments and technical signals for ImmunityBio (IBRX).
NASDAQ:IBRXLong
by meitshels_smell_trades
Buy the Dip, Sell the Rip: 100% Profit in 2 Weeks.Immunity Bio (IBRX) could bounce soon. - The price is touching the trend line that has served as resistance since October 2023. - The RSI is slowly moving above the moving average. - The RCI indicator shows a triple bottom with all three trend lines (short, middle, and long). - On the chart, the price is touching the lower line of the Bollinger Bands. The price had been in an uptrend since October 2023 and dipped in May 2024. However, the dip might end soon, as the price is struggling to move lower from this point.
NASDAQ:IBRXLong
by ValerianK
Why trading seems to be difficult ??Fianancial market management is the only business ,where investor or a trader can take decision of max loss he /she could bears , while in offline business seems to predict how much max loss we could experience ! because we can build a house then after we could even face will a earth quake and losing 100% of that house, in my experience of above 5 years , what i have see in this industry, most people spend their decades and decades trying to master a winning system and ignoring that , fixing their mental state or their psychology is the most password! the second security no one is engaging in learning how to choose market to trade.
NASDAQ:IBRXEducation
by nog50traders
2
$IBRX A Step Towards Better ImmunotherapyWhile most oncological treatments focus on bombarding the body with toxic materials in hopes of killing cancerous cells, ImmunityBio, Inc. (Nasdaq: IBRX) utilizes immunology in order to find a solution. Its treatments usually focus on catalyzing NK cells, and T cells, which then kill cancerous cells. Currently, IBRX has a chance to showcase one of its treatments due to its upcoming catalyst. IBRX has a PDUFA action date of May 23, 2023, for QUILT 3.032 BLA. In short, the FDA will decide if it grants IBRX a biological license for QUILT 3.032. In Layman’s terms, if IBRX obtains this license then IBRX will be granted market access which will allow the company to start realizing revenues. In light of this, IBRX stock could be one to buy in anticipation of the FDA’s decision. IBRX Fundamentals QUILT 3.032 is a bladder cancer treatment that boosts the immune system and allows the body to fend off cancerous cells. That said, QUILT 3.032 has proven itself as an effective treatment. According to data published in NEJM Evidence 58 out of 82 patients exposed to QUILT 3.032 experienced a complete response, which basically means that all signs of cancer were eliminated in 71% of the patients. These are significant margins from an oncology standpoint, and will probably play a role in the FDA’s decision concerning whether or not to approve QUILT 3.032’s MLA. In the US, bladder cancer is the fourth most common solid-diagnosed malignancy in men and twelfth in women. Additionally, the American Cancer Society estimates that there will be 82,290 new cases in 2023. Since it is such a common cancer, demand for its treatment is also high – meaning that if QUILT 3.032 enters the market, it is not likely to experience any shortage in demand. In case QUILT 3.032 is approved by the FDA, a short squeeze may occur in IBRX stock given its high short data. Currently, IBRX has a short interest of 24% and a 100% utilization rate. With investors anticipating the FDA’s decision regarding the company’s bladder cancer treatment, IBRX stock may be an attractive buy at current levels. Currently, IBRX’s biggest risk is its cash burn rate as its operating expenses ballooned from $95 million to $111 million YoY in Q1 2023. This risk is compounded by the fact that IBRX currently has 88 million in cash on hand at the moment. If the QUILT 3.032 BLA is approved then the dilution risk may be mitigated since the company would raise capital at a higher PPS which would limit the extent of the dilution. IBRX Financials According to its Q1 2023 report, IBRX’s total assets decreased from $362 million to $343 million QoQ. Its current cash and cash equivalents also decreased from $104 million to only $88 million. On the other hand, its liabilities increased from $812 million to $875 million during the same period. On a brighter note, its grant revenues increased from $14 thousand to $360 thousand YoY. That said, its operating expenses increased from $95 million to $111 million YoY. As a result, its net loss increased from $102 million to $116 million. If QUILT 3.032’s BLA is approved, then IBRX will become capable of producing product revenue which will assist IBRX’s finances and will lower the likelihood of dilution for IBRX stock moving forward. Technical Analysis IBRX is a neutral trend trading in a sideways channel between its $2.78 support and its $3.69 resistance below the 200 MA. Looking at the indicators, IBRX is trading below the 200, 50, and 21 MAs. Meanwhile, the MACD is neutral and the RSI is approaching oversold at 38. It is worth noting that there is a gap near $6.1 that could be filled if IBRX’s bladder cancer treatment is approved by the FDA. As for its fundamentals, IBRX has a major upcoming catalyst in the PDUFA action which is set to take place on May 23rd. Since the company would be able to launch its treatment if approved, the IBRX stock price could soar on positive news. With the stock trading near support, investors could find a good entry at the current PPS in anticipation of the FDA’s decision. IBRX Forecast The FDA’s decision regarding QUILT 3.032’s BLA will come out on May 23. That said, QUILT 3.032 produced impressive results in its trials. In one study, 58 out of 82 patients experienced a complete response which is extremely significant since it means that all traces of cancer were gone. Due to those trials, IBRX’s BLA is likely to be approved which would grant QUILT 3.032 market access and cause IBRX stock to soar given its high short interest.
NASDAQ:IBRX
by Penny_Stocks_Today
$IBRX - If $11.23 breaks, $8.78 possibleHas been unable to find bottom yet. There is a chance of consolidating or reversal from around $11.23 area due to oversold condition. If there is further break down, the next support area is $8.78, which could be a strong support. Good case - consolidate or reversal from $11.23 Best case - $12.70 Bad case - $8.78 ——————————————————— How to read my charts? - Matching color trend lines shows the pattern. Sometimes a chart can have multiple patterns. Each pattern will have matching color trend lines. - The yellow horizontal lines shows support and resistance areas. - Fib lines also shows support and resistance areas. - The dotted white lines shows price projection for breakout or breakdown target. Disclaimer: Do your own DD. Not an investment advice.
NASDAQ:IBRX
by PaperBozz
From the Watchlist. IBRX. Might be a mover.IBRX somehow doesn't give much chart data from trading view, but it could possibly be entering a post-correction phase. It has been on my watchlist and it looks like it could have some ideas about the direction it wants to go. I see three possible scenarios: - 1) buyers begin to notice the stock and it goes up like a frickin rocket. (best) - 2) buyers don't really notice it, it and our current rally gets sold into. We see more consolidation, possibly missing the rally that breaks out the trend. (cautious) - 3) This is a false rally, the company is failing. Price falls to 13, maybe 10. (worst) The reversal pattern it put in, to me, is a very legitimate one I see a double bottom and a higher high. That's like rice and beans, you can probably live off of it. Everything I know is telling me to buy, but as I am fairly new to stocks, it's the things I don't know that are keeping me out at the moment. But, that wedge does make me think of cheese. This game is fun. It's like spy vs spy. Hard to tell if I'm setting the mousetrap, or if I am the mouse. But, darn it if it isn't a little exciting.
NASDAQ:IBRXLong
by emehoke